BR112012016128A8 - Agente terapêutico (y-39983) para disfunção endotelial da córnea - Google Patents

Agente terapêutico (y-39983) para disfunção endotelial da córnea

Info

Publication number
BR112012016128A8
BR112012016128A8 BR112012016128A BR112012016128A BR112012016128A8 BR 112012016128 A8 BR112012016128 A8 BR 112012016128A8 BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A8 BR112012016128 A8 BR 112012016128A8
Authority
BR
Brazil
Prior art keywords
corneal endothelial
endothelial cells
compound
therapeutic agent
corneal
Prior art date
Application number
BR112012016128A
Other languages
English (en)
Other versions
BR112012016128A2 (pt
Inventor
Takahashi Hiroaki
Sakamoto Yuji
Kida Tetsuo
Tarui Takeshi
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Publication of BR112012016128A2 publication Critical patent/BR112012016128A2/pt
Publication of BR112012016128A8 publication Critical patent/BR112012016128A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

USOS DE (R)-(+)-N-(1H-PIRROL[2,3-B]PIRIDIN-4- IL)-4-(1-AMINOETIL) BENZAMIDA. A presente invenção refere-se a um meio para o tratamento eficaz e conveniente de doenças em que células endoteliais da córnea pobres em termos de capacidade proliferativa in vivo são lesionadas. A presente invenção oferece um agente terapêutico para disfunção endotelial da córnea contendo (R)-(+)-N-(1H-pirrol[2,3-b]piridin-4-il)-4 -(1-aminoetil)benzamida ou um sal farmacologicamente aceitável da mesma (composto (Ia)) como princípio ativo, um agente para promover adesão de células endoteliais da córnea, contendo o composto (Ia), um meio de cultura para células endoteliais da córnea, contendo o agente para promover adesão, um implante para ceratoplastia endotelial da córnea contendo células endoteliais da córnea, substrato e composto (Ia), e um método de produção de uma preparação de endotélio corneano, incluindo uma etapa de cultivar células endoteliais da córnea usando o meio de cultura.
BR112012016128A 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea BR112012016128A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (2)

Publication Number Publication Date
BR112012016128A2 BR112012016128A2 (pt) 2016-05-31
BR112012016128A8 true BR112012016128A8 (pt) 2017-12-05

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016128A BR112012016128A8 (pt) 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea

Country Status (10)

Country Link
US (1) US20120288482A1 (pt)
EP (1) EP2519237A1 (pt)
JP (2) JP5750444B2 (pt)
KR (1) KR20120099147A (pt)
CN (1) CN102770136A (pt)
BR (1) BR112012016128A8 (pt)
CA (1) CA2785851A1 (pt)
MX (1) MX2012007671A (pt)
RU (1) RU2563141C2 (pt)
WO (2) WO2011080984A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58526B1 (sr) * 2011-12-06 2019-04-30 Astellas Inst For Regenerative Medicine Postupak usmerene diferencijacije koja proizvodi kornealne endotelijalne ćelije
US11624053B2 (en) 2013-11-27 2023-04-11 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
US10959997B2 (en) 2013-12-27 2021-03-30 Kyoto Prefectural Public University Corporation Combined agent for cell therapy of corneal endothelial cell
US10034885B2 (en) 2014-09-24 2018-07-31 Kowa Company, Ltd. Corneal thickness modulating agent
CA2965770C (en) 2014-10-31 2024-02-13 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
US20190083543A1 (en) * 2016-02-15 2019-03-21 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1752456B1 (en) * 2004-06-03 2015-08-26 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
EP1829876A4 (en) * 2004-11-26 2009-04-01 Asahi Kasei Pharma Corp NITROGENIC TRICYCLIC COMPOUND
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
JPWO2006095844A1 (ja) * 2005-03-10 2008-08-21 田辺三菱製薬株式会社 医薬製剤
US10052411B2 (en) * 2006-01-19 2018-08-21 Senju Pharmaceutical Co., Ltd. Methods of treating corneal related diseases by corneal endothelial preparation which enables cells to grow in vivo
US20090247552A1 (en) * 2006-07-31 2009-10-01 Shirou Sawa Aqueous liquid preparation containing amide compound
KR20240045364A (ko) 2007-08-29 2024-04-05 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
KR20120099147A (ko) 2012-09-06
JP2013515676A (ja) 2013-05-09
JP2015155460A (ja) 2015-08-27
JP5750444B2 (ja) 2015-07-22
CN102770136A (zh) 2012-11-07
US20120288482A1 (en) 2012-11-15
WO2011080984A1 (en) 2011-07-07
BR112012016128A2 (pt) 2016-05-31
MX2012007671A (es) 2012-08-23
RU2563141C2 (ru) 2015-09-20
CA2785851A1 (en) 2011-07-07
EP2519237A1 (en) 2012-11-07
RU2012132443A (ru) 2014-02-10
WO2011081221A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
BR112012016128A8 (pt) Agente terapêutico (y-39983) para disfunção endotelial da córnea
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2013013560A (es) Tratamiento de la degeneracion del disco intervertebral mediante el uso de celulas humanas derivadas de tejido del cordon umbilical.
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2008054544A3 (en) Method for delivery across the blood brain barrier
BRPI0608152A2 (pt) formulações para tratamento ocular
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
SI1778680T1 (sl) Spirociklični cikloheksanski derivati
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
MX338088B (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
EA201270629A1 (ru) Новые полиморфные формы метил(4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил)карбамата
WO2011118954A3 (ko) 사람 하비갑개 유래 중간엽 기질세포로부터 연골, 골, 신경세포 또는 지방세포를 분화시키는 방법
JP2013515676A5 (pt)
BR112014009761B8 (pt) Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2008121422A3 (en) Implantable cell matrix composition for delivery of bioactive compounds
BR112013026644A2 (pt) método para a modulação da atividade de citocina
BRPI0716423A2 (pt) Terapêutica promotora de restauração de nervo espinhal contendo desacil grelina ou seus derivados como ingrediente ativo
MX350662B (es) Composiciones farmaceuticas que comprenden 7- (1h- imidazol-4-ilmetil) -5,6,7,8,-tetrahidroquinolina para el tratamiento de enfermedades y dolencias de la piel.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SENJU PHARMACEUTICAL CO., LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018.